DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability
Topical application must penetrate the skin barrier, and even the best formulations lose a significant portion of the active compound during that process
Maintenance dosing after achieving goal weight often allows reduction to 1.8-2.0mg weekly for both peptides, providing 20-30% cost savings while sustaining results
The FDA perspective on compounded semaglutide Understanding the regulatory landscape helps you make informed decisions about using compounded sublingual drops
GLP-1 drugs can cause side effects such as nausea, vomiting, diarrhea, and, less commonly, pancreatitis (a serious inflammation of the pancreas)